Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Bayer CEO says supply shortages cut crop protection sales in 2022

Published 15/09/2022, 14:02
Updated 15/09/2022, 14:06
© Reuters. FILE PHOTO: Werner Baumann, CEO of Bayer AG, addresses the German drugmaker's annual results news conference in Leverkusen, Germany, February 27, 2020. REUTERS/Wolfgang Rattay

By Ross Kerber

CAMBRIDGE, Mass. (Reuters) - Supply chain shortages cost  Bayer AG up to 3% of lost sales in its crop protection business this year, CEO Werner Baumann said on Wednesday, adding he expects constraints to continue in that segment and others.

Global supply chains must rebalance before the situation eases, Baumann said in an interview with Reuters.

"We do see shortages and we are affected by non-availability or insufficiency of products, that limits our ability to take advantage of the market opportunities that are out there," Baumann said.

The German company's crop-protection business includes herbicides, insecticides and other products to maximize crop output at a time of low global grain supplies. Widespread chemical shortages this year disrupted U.S. farmers' production strategies and raised their costs, contributing to rising food prices and inflation.

Baumann said the company "could easily see" up to 3% more growth in its crop protection business if it had full product availability in 2022. He declined to give a figure for 2023, but said other lines like the multi-vitamin segment of its consumer health business also face shortages.

Causes include Russia's invasion of Ukraine. Also, many businesses could not ramp up quickly as the global COVID-19 pandemic eased.

"We would need a full rebalancing" of the supply chain, he said.

Baumann spoke during a press event that Bayer held to show off a new laboratory space it opened this year in Cambridge, Massachusetts adjacent to the Massachusetts Institute of Technology.

A Bayer representative said his comments did not change recent earnings guidance. In the interview Baumann declined to comment on a recent report the company has begun a search for his successor.[L8N30K2TF]

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Baumann also said it was too soon to tell how a June U.S. Supreme court decision opening the door to new abortion restrictions might affect contraceptive sales.

Bayer's sales of such products fell around 10% as people formed fewer long-term relationships during the pandemic, he said. Sales will likely recover in coming quarters, Baumann said, citing how many pubs are again crowded with people.

"Life is back to normal, at least based on what I’ve seen in Boston," he said.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.